Global DNA Vaccines Market 2019-2027: Market to Witness a CAGR of 42.03% -

DUBLIN--()--The "Global DNA Vaccines Market 2019-2027" report has been added to's offering.

The author predicts that the global market for DNA vaccines would witness a CAGR of 42.03% over the forecast period 2019-2027.

The increase in cases of chronic and infectious diseases, swelling usage of DNA vaccines for animal healthcare and a surge in the development of new vaccines are driving the global DNA vaccines market. On the other hand, issues like the lack of legal & ethical framework and strict regulations by the government restrict the growth of the market.

Opportunities like steady vaccines that are easier to store & transport, rising number of clinical trials on humans and growth in the demand for gene therapy supplement the growth of the market. However, factors such as variation in the regulatory pathway and the points of consideration regarding environmental valuation are proving to be a massive challenge for the DNA vaccines market growth.

Regional Outlook

The regions of Europe, Asia-Pacific, Latin America, the Middle East and Africa and North America form the global DNA vaccines market. North America is the global leader in the DNA vaccines market. The North America DNA vaccines market is primarily driven by high investments to support the development of human DNA vaccines in the countries of the US and Canada.

Furthermore, a large number of pets that are one of the primary consumers of DNA vaccines, also positively influence the growth of the DNA vaccines market, since a significant percentage of the population in this region owns pets. According to the National Center for Biotechnology Information, the Canadian government made an investment of $440 million in 2015 for the advancement & development of DNA vaccines in the country, focusing on both the humans and animals.

Key Topics Covered:

1. Global DNA Vaccines Market - Summary

2. Industry Outlook

2.1. Market Definition

2.2. Porter's Five Forces Outlook

2.3. Vendor Scorecard

2.4. Value Chain Outlook

2.5. Key Insights

2.6. Regulatory Framework

2.7. Key Buying Outlook

2.8. Market Drivers

2.8.1. Surge in New Vaccine Development

2.8.2. Rising Usage of DNA Vaccines for Animal Healthcare

2.8.3. Rising Prevalence of Chronic and Infectious Diseases

2.9. Market Restraints

2.9.1. Lack of Legal and Ethical Framework

2.9.2. Stringent Government Regulations

2.10. Market Opportunities

2.10.1. Growing Demand for Gene Therapy

2.10.2. Steady Vaccines Are Easy to Store and Transport

2.10.3. Increasing Number of Clinical Trials on Humans

2.11. Market Challenges

2.11.1. Variation in the Regulatory Pathway and the Points of Consideration Regarding Environmental Valuation

3. DNA Vaccines Market Outlook - by Type

3.1. Animal DNA Vaccine

3.2. Human DNA Vaccine

4. DNA Vaccines Market Outlook - by Application

4.1. Human Disease

4.2. Veterinary Disease

5. DNA Vaccines Market Outlook - by Technology

5.1. Plasmid DNA Vaccines

5.2. Plasmid DNA Delivery

6. DNA Vaccines Market Outlook - by Region

7. Competitive Landscape

7.1. Astellas Pharma, Inc.

7.2. Dendreon Corporation (Acquired by Sanpower Group)

7.3. Eli Lilly and Company

7.4. Eurogentec S.A.

7.5. Glaxosmithkline, Inc.

7.6. Inovio Pharmaceuticals, Inc.

7.7. Madison Vaccines Incorporated (Mvi)

7.8. Merck & Co.

7.9. Merial Limited (Acquired by Boehringer Ingelheim)

7.10. Novartis AG

7.11. Sanofi

7.12. Vgxi

7.13. Vical, Incorporated

7.14. Xenetic Biosciences, Inc.

7.15. Zoetis, Inc.

For more information about this report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900